-
Mashup Score: 1Darovasertib, Crizotinib Combination Advances Into Phase 2 Expansion for GNAQ/11 Metastatic Cutaneous Melanoma - 6 month(s) ago
The advancement is based on previous observations of preliminary clinical efficacy. There are currently no FDA-approved therapies for this patient population.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial - 6 month(s) ago
This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.
Source: www.jto.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Authors compared #brigatinib to #alectinib in this open-label, phase 3 trial for efficacy & safety for pts w/ALK+NSCLC after disease progression on #crizotinib but found that brigatinib was not superior to alectinib for PFS in crizotinib-treated pts. https://t.co/0qVGvX8zl2 #LCSM https://t.co/Ojz9itZ8Dw
-
-
Mashup Score: 2
Promising results from a type C meeting with the FDA has led to a phase 2/3 trial of darovasertib and crizotinib being initiated in 2023 for patients with first-line HLA-A2 negative metastatic uveal melanoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
BackgroundAlthough anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have impressive response in advanced lung adenocarcinoma with anaplastic lymphoma kinase (ALK) fusion, no guidelines point to the potential benefits of neoadjuvant ALK-TKIs for N3 unresectable locally advanced lung cancer. Current ongoing clinical trials mainly focus on the efficacy of neoadjuvant ALK-TKIs in…
Source: FrontiersCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
With an overall response rate of 50% and greater than 5 months median progression-free survival in patients with first-line metastatic uveal melanoma, darovasertib and crizotinib shows a compelling clinical efficacy profile.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Original Article from The New England Journal of Medicine â Brigatinib versus Crizotinib in ALK-Positive NonâSmall-Cell Lung Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Successful Treatment of Patients with Refractory HighâGrade Serous Ovarian Cancer with GOPCâROS1 Fusion Using Crizotinib: A Case Report - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Association of Programmed DeathâLigand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma KinaseâPositive Lung Adenocarcinoma Receiving Crizotinib #AnaplasticLymphomaKinase #Crizotinib #FusionVariant #LungCancer https://t.co/EGfGoJ757i https://t.co/pVP5Vkktao
-
-
Mashup Score: 1JNCCN 360 - NSCLC - WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC - 3 year(s) ago
By: Julia Fiederlein Posted: Friday, February 12, 2021 According to Julien Mazieres, MD, PhD, of Toulouse University Hospital, France, and colleagues, in the phase III CROWN trial, the third-generation ALK inhibitor lorlatinib seemed to significantly improve progression-free survival compared with crizotinib…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
đ¨NEW: IDEAYA Biosciences has announced the phase 2 expansion of the combination #darovasertib and #crizotinib for the study of its efficacy in patients with GNAQ/11 metastatic cutaneous #melanoma. https://t.co/3oySDitRkW